- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Ondine Biomedical - New study confirms nose is key source of infection | - | RNS | ||
| Mi | EARNINGS AND TRADING: Nichols trading in line; Ondine revenue doubles | 1 | Alliance News | ||
| Mi | Ondine reports significant financial growth | 1 | Sharecast | ||
| Mi | Ondine Biomedical - Corporate and Trading Update | 1 | RNS | ||
| Mo | Ondine Biomedical celebrates use of Steriwave in Australian hospital | 1 | Alliance News | ||
| Mo | Ondine Biomedical - Steriwave in first Australian hospital | - | RNS | ||
| 15.04. | Ondine Biomedical's Steriwave reduces SSI's by 32%, study shows | 1 | Alliance News | ||
| 15.04. | Ondine Biomedical - 32% Fewer SSIs After Steriwave Replaced Mupirocin | - | RNS | ||
| 10.04. | Ondine Biomedical shares jump as Steriwave approved by HCA Healthcare | 9 | Alliance News | ||
| 10.04. | Ondine Biomedical - Steriwave authorized for use by HCA UK | 5 | RNS | ||
| 04.04. | Ondine says introduction of Steriwave in ICU market could boost sales | 1 | Alliance News | ||
| 04.04. | Ondine Biomedical - Entry into ICU market expands revenue potential | - | RNS | ||
| 28.03. | Ondine Biomedical appoints new interim chief financial officer | 1 | Alliance News | ||
| 28.03. | Ondine Biomedical - Appointment of Interim Chief Financial Officer | - | RNS | ||
| 25.03. | Ondine Biomedical - First commercial adoption of Steriwave by the NHS | - | RNS | ||
| 21.03. | Ondine Biomedical - Steriwave study shows 77% drop in antibiotic use | 1 | RNS | ||
| 15.03. | IN BRIEF: Ondine Biomedical says commercial progress ahead of forecast | 2 | Alliance News | ||
| 15.03. | Ondine Biomedical - Replacement: Steriwave deploying in 8 new sites | - | RNS | ||
| 15.03. | Ondine Biomedical - Steriwave deploying in eight new sites | - | RNS | ||
| 05.03. | Ondine Biomedical - Ondine starts first UK health economics study | - | RNS |
Seite:
1 2 3 Weiter >>
44 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 9,485 | +3,55 % | Evotec, HelloFresh, K+S, Lanxess, Varta, Zalando und Co. - Aktien-Positionen der Shortseller | Wer Aktien leer verkauft, das sogenannte Shortselling, muss Transparenzpflichten erfüllen. Wir werfen einen Blick auf aktuelle Shortseller-Meldungen. Geregelt sind diese in der EU-Leerverkaufsverordnung... ► Artikel lesen | |
| VERA THERAPEUTICS | 38,690 | 0,00 % | Aktien New York Ausblick: Vor dem Start in die Berichtssaison stabil erwartet | NEW YORK (dpa-AFX) - Nach einem schwachen Handelsverlauf am Vortag dürften sich die US-Börsen am Donnerstag stabilisieren. Am Mittwoch hatte eine überraschend hohe Inflation im Monat März die Hoffnungen... ► Artikel lesen | |
| IMMUNOVANT | 27,750 | 0,00 % | Should You Hold Immunovant (IMVT)? | ||
| KYMERA THERAPEUTICS | 33,350 | 0,00 % | Kymera Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) | ||
| RECURSION PHARMACEUTICALS | 7,840 | 0,00 % | Best biotech stocks to buy and hold in 2024: VKTX, SANA, RXRX | ||
| ARCTURUS THERAPEUTICS | 26,170 | 0,00 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 44,200 | 0,00 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting | ||
| ARCUTIS BIOTHERAPEUTICS | 8,590 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Appoints David Topper as Chief Financial Officer | WESTLAKE VILLAGE, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage company focused on developing meaningful innovations in immuno-dermatology... ► Artikel lesen | |
| DYNE THERAPEUTICS | 23,695 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer | WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for... ► Artikel lesen | |
| DAY ONE BIOPHARMACEUTICALS | 13,210 | 0,00 % | Day One Biopharmaceuticals, Inc.: Day One's OJEMDA (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor | First and only FDA-approved type II RAF inhibitor for patients with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement, or BRAF V600 mutation RAPNO LGG overall response rate... ► Artikel lesen | |
| KEROS THERAPEUTICS | 54,19 | 0,00 % | Prozessmanagement in der Gemeinschaftsverpflegung / Keros Consult optimiert Warenwirtschaft für Eichhof-Stiftung Lauterbach | Düsseldorf (ots) - Ab sofort unterstützt Keros Consult, eine hundertprozentige Tochtergesellschaft der Klüh-Gruppe, die Eichhof-Stiftung Lauterbach bei der Optimierung ihrer Bestell- und Produktionsprozesse... ► Artikel lesen | |
| BEAM THERAPEUTICS | 21,600 | 0,00 % | Expert Ratings For Beam Therapeutics | ||
| SANA BIOTECHNOLOGY | 8,500 | 0,00 % | Sana Biotechnology, Inc: Sana Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates | Goal to treat 40-60 patients in 2024 in four trials across seven indications in oncology, B-cell mediated autoimmune diseases, and type 1 diabetes Early SC291 data from ongoing ARDENT trial in relapsed/refractory... ► Artikel lesen | |
| ARVINAS | 31,600 | 0,00 % | Arvinas Inc.: Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer | NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 23,830 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, April 22, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide... ► Artikel lesen |
Das Unternehmen ONDINE BIOMEDICAL INC CDIS kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,005 (-9,38 %) liegt der Kurs bei 0,044 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
